Anti-RABV Glycoprotein G Reference Antibody (Rafivirumab, RUO)

Description: Rafivirumab (BS10517) is a research-grade recombinant antibody targeting G/Glycoprotein. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1,lambda
Species reactivity: Rabiesvirus(RABV)
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.99mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: G/Glycoprotein
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CR57,NM57,S057,CR57,SO57,Ormutivimab,CAS:944548-37-2
Background: Glycoprotein is a ~58 kDa protein. Attaches the virus to host cellular receptor, inducing endocytosis of the virion by using different host proteins including TFRC, GRM2 and ITGB1. In the endosome, the acidic pH induces conformational changes in the glycoprotein trimer, which trigger fusion between virus and cell membrane. There is convincing in vitro evidence that the muscular form of the nicotinic acetylcholine receptor (nAChR), the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus entry into cells.
Note: For research use only. Not suitable for clinical or therapeutic use.